Search

Displaying results 7021 - 7030 of 10000 in total
  1. Drug

    N-acetyl-beta-neuraminic acid

    go.drugbank.com/drugs/DB04265
    Experimental

    An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518)

    Synonyms: N-acetyl-β-neuraminic acid, N-acetyl-beta-neuraminic acid
  2. Drug

    Calcium silicate

    go.drugbank.com/drugs/DB13829
    Investigational

    Categories: Drugs for Acid Related Disorders
  3. Drug

    Aconiazide

    go.drugbank.com/drugs/DB17731
    Experimental

    Categories: Drugs for Treatment of Tuberculosis
  4. Drug

    Satraplatin

    go.drugbank.com/drugs/DB04996
    Investigational

    As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies. … Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy.

  5. Drug

    Chromic citrate

    go.drugbank.com/drugs/DB14526
    Experimental

  6. Drug

    Proxazole

    go.drugbank.com/drugs/DB13819
    Experimental

    Categories: Drugs for Functional Gastrointestinal Disorders
  7. Drug

    Histapyrrodine

    go.drugbank.com/drugs/DB13479
    Experimental

    Categories: Antihistamines for Systemic Use
  8. Drug

    Bekanamycin

    go.drugbank.com/drugs/DB13673
    Investigational

    Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index, Antibacterials for Systemic Use
  9. Drug

    Lysozyme

    go.drugbank.com/drugs/DB13260
    Investigational

    Mixtures: E-zyme B6 Troche, E-zyme B6 Soothing LiquidCategories: Antiinfectives for Systemic Use
  10. Drug

    DDP-225

    go.drugbank.com/drugs/DB05642
    Investigational

    DDP225 is both a noradrenaline reuptake inhibitor and a serotonin type 3 receptor (5-HT3) antagonist. … The unique combination of noradrenaline reuptake inhibition and 5-HT3 antagonism in one orally delivered compound represents a novel approach to treating IBS-d and other functional GI diseases.